ANKRD30A and breast cancer: A novel breast cancer differentiation antigen, designated as New York-Breast-1 (NY-BR-1), was identified by a serological cloning strategy (SEREX) [1, 2] and could be a possible target for immunotherapy for breast cancer patients [3].